Volume 92 Issue 19 | p. 6 | News of The Week
Issue Date: May 12, 2014

Pfizer Chases Merger Deal

Acquisitions: Drug firm pursues AstraZeneca despite rejections and U.K. concerns
Department: Business
Keywords: pharmaceuticals, acquisitions, taxation, R&D, employment

Pfizer is still pushing to create a tax-advantaged U.K.-based drug giant even after AstraZeneca rejected its latest $106 billion takeover offer. To bolster Pfizer’s position, CEO Ian C. Read has promised British Prime Minister David Cameron that the company will keep significant operations in the U.K. The company also is highlighting the benefits of a merger in a new infographic on its merger-related website.

AstraZeneca . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society